Home » More Heartburn From J&J’s Natrecor
More Heartburn From J&J’s Natrecor
December 4, 2007
Johnson & Johnson announced that it will take a noncash charge of $440 million from a writedown related to a decline in sales of its acute heart failure drug, Natrecor.
The Motley Fool